Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangement, Collaborative Arrangements and Research and Development Arrangement - Summarized Financial Information of Discontinued Operations (Details) - USD ($) $ in Millions			12 Months Ended
		Dec. 31, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Costs and expenses:
Discontinued operations––net of tax			$ (15)	$ 6	$ (434)
Certain legal matters, net	[1]		474	230	182
Discontinued Operations [Member]
Income Statement Disclosures
Total revenues	[2]		0	0	277
Costs and expenses:
Cost of sales	[2]		0	0	204
Selling, informational and administrative expenses	[2]		0	8	26
Research and development expenses	[2]		0	0	9
Acquired in-process research and development expenses	[2]		0	0	0
Amortization of intangible assets	[2]		0	0	45
Restructuring charges and certain acquisition-related costs	[2]		0	0	2
Other income	[2]		(11)	(20)
Other deductions	[2]				365
Pre-tax income/(loss) from discontinued operations	[2]		11	12	(375)
Provision/(benefit) for taxes on income	[2]		26	13	(107)
Income/(loss) from discontinued operations––net of tax	[2]		(15)	(1)	(268)
Pre-tax gain/(loss) on sale of discontinued operations	[2]		0	10	(211)
Provision/(benefit) for taxes on income	[2]		0	2	(44)
Gain/(loss) on sale of discontinued operations––net of tax	[2]		0	7	(167)
Discontinued operations––net of tax	[2]		$ (15)	6	$ (434)
Discontinued Operations, Disposed of by Sale [Member] | Meridian [Member]
Costs and expenses:
Gain/(loss) on sale of discontinued operations––net of tax		$ (167)
Discontinued Operations, Disposed of by Sale [Member] | Meridian [Member] | Epi Pen [Member]
Costs and expenses:
Certain legal matters, net				$ 345

[1] 2023 primarily includes certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer and legal obligations related to pre-acquisition matters. 2022 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer. 2021 primarily included certain product liability expenses related to products discontinued and/or divested by Pfizer, and to a lesser extent, legal obligations related to pre-acquisition matters.

[2] In 2023 and 2022, Discontinued operations—net of tax relates to post-close adjustments. In 2021, Discontinued operations—net of tax primarily includes (i) the operations of Meridian prior to its sale on December 31, 2021 recognized in Income/(loss) from discontinued operations—net of tax, which includes a pre-tax expense to resolve an MDL relating to EpiPen against the Company in the U.S. District Court for the District of Kansas for $345 million; and (ii) the after tax loss of $167 million related to the sale of Meridian recognized in Gain/(loss) on sale of discontinued operations––net of tax. To a much lesser extent, Discontinued operations—net of tax in 2021 also includes the operations of the Mylan-Japan collaboration prior to its termination on December 21, 2020 and post-close adjustments directly related to our former Upjohn and Nutrition discontinued businesses, including adjustments for tax, benefits and legal-related matters recognized in Income/(loss) from discontinued operations—net of tax.